PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 11, 2026Diabetes Obesity and Metabolism2 citations

Neuroprotective effects of semaglutide targeting the left temporal lobe in adults with overweight or obesity: A 24‐week multimodal neuroimaging study

View Full Paper
FMF X MengXAXiang AoXLXiangming Lin

Key Points

  • This study aimed to assess the neuroprotective effects of semaglutide on brain structure in adults with overweight or obesity.
  • Conducted a prospective, single-arm intervention with 26 adults receiving semaglutide weekly for 24 weeks.
  • Performed multimodal assessments using structural and functional MRI pre- and post-intervention.
  • Evaluated cognitive function through standardized computerized tasks and metabolic profiles.
  • Significant improvement in metabolic health, including weight loss and reduced glycolipid levels.
  • Increased grey matter volume in the left inferior temporal gyrus; decreased fractional amplitude of low-frequency fluctuations and regional homogeneity in the left temporal lobe.
  • No significant correlation found between neurobiological changes and the degree of weight loss.

Abstract

Abstract Background Since obesity and its associated metabolic dysregulation are recognized risk factors for cognitive decline, this study investigated whether semaglutide, a glucagon‐like peptide‐1 receptor agonist proven to have cardiometabolic benefits, could provide potential neuroprotective effects on brain structure and function. Methods In a prospective, single‐arm intervention study, 26 adults with overweight or obesity received 1.0 mg semaglutide weekly for 24 weeks. Multimodal assessments were performed pre‐ and post‐intervention, including structural and functional MRI for analysing grey matter volume (GMV), fractional amplitude of low‐frequency fluctuations (fALFF), and regional homogeneity (ReHo). Cognitive function was evaluated using standardized computerized tasks (the Flanker and N‐back). Additionally, comprehensive metabolic profiles were assessed, including markers of glucose and lipid metabolism along with inflammatory cells. Results Semaglutide treatment significantly improved systemic metabolic health, inducing weight loss and reducing glycolipid levels and leukocyte counts. Neuroimaging revealed targeted neurobiological effects in the left temporal lobe: specifically, increased GMV in the left inferior temporal gyrus and decreased fALFF in the left middle and superior temporal gyri alongside reduced ReHo in the left middle temporal gyrus. These neural changes occurred despite no significant improvement in cognitive task performance. Importantly, the alterations in brain structure and function were not statistically correlated with the degree of weight loss or metabolic improvement. Conclusions A 24‐week semaglutide intervention induces significant neurobiological remodelling in the left temporal lobe of adults with overweight or obesity. These central effects are independent of the drug's systemic metabolic improvements, offering new evidence for its potential neuroprotective role.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Meng et al. (2026) studied this question.

synapsesocial.com/papers/698c1c53267fb587c655eb73https://doi.org/10.1111/dom.70524
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity2025 · 47 citations
  2. 2Semaglutide's Role in Modulating the Brain-Heart Axis: Implications for Obesity and Alzheimer’s Disease Co-management2025
  3. 3Beyond Weight Loss: Early Real-World Evidence of Semaglutide in Obesity2026
  4. 4Semaglutide treatment in hypothalamic obesity: Two-Year outcomes on body composition, appetite, and quality of life2025 · 10 citations
  5. 5Semaglutide in cognitive dysfunction: neuroprotective potential, clinical trial limitations, and a prevention-focused framework2026